News | February 12, 2015

ACC, Symphony Health Solutions Create New Cardiac Research Platform

Platform contains medical history of 5 million anonymized patients

February 12, 2015 – Symphony Health Solutions (SHS) and the American College of Cardiology announced the completion of a new research platform. The HIPAA-compliant platform combines anonymized patient-level data from the ACC's National Cardiovascular Data Registry (NCDR) with SHS's Integrated Dataverse, which includes prescription, medical and hospital claims. The newly integrated data includes approximately 5 million anonymized patients with up to six years of observed diagnoses, procedures, therapies and related findings.

Information from a large set of patients that is both broad in scope and deep in detail has, before now, been difficult to obtain — yet vital to improve care. The creation of a new analytical platform now enables a wide range of new analyses to help achieve that goal. The organizations will use the combined data sources to complete research projects focused on clinical outcomes, comparative effectiveness, therapy adoption and use, and population health, as well as additional studies and projects of interest. These analyses of patterns and treatments can ultimately improve care, enhance outcomes and reduce unnecessary healthcare costs.

"This analytic platform is ground-breaking in the level of data it will provide," said John S. Rumsfeld, M.D., Ph.D., FACC, chief science officer of the American College of Cardiology National Cardiovascular Data Registries. "The partnership between ACC and SHS brings together the detailed clinical data from the registries with the longitudinal data resources of SHS. This creates a synergy that can yield critical insights on improving cardiovascular care and patient outcomes."

Analytics solutions produced through the collaboration will have broad applicability across the healthcare market. Entities such as life sciences organizations and the government, with whom ACC and SHS engage today, will also benefit from the new research offerings.

For more information: www.symphonyhealth.com or www.acc.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now